Project: Improving personalised glioblastoma care by intertwined immunomics and artificial intelligence approaches

Acronym IPerGlio (Reference Number: ERAPERMED2022-245)
Duration 01/05/2023 - 30/04/2026
Project Topic New treatment strategies to improve patient care and quality of life (QoL) of glioblastoma (GBM) patients are urgently needed. Standard therapy has not changed for over 15 years, and GBM patients have a median survival of less than 15 months. Around 25% of clinical trials in GBM evaluate immunotherapies and several have reported long-term survival benefits in 10-20% of patients. Tumour mutational burden (TMB) and inflammation have been linked to immunotherapy responsiveness in GBM. A clear clinical benefit of immunotherapy has been hampered by the lack of biomarkers in this highly heterogeneous disease. All GBMs recur and recurrence can be limited only via a strategy considering clinical and immunological correlates evaluated in a sex- and age-specific perspective. These correlates must be integrated with key lifestyle/environmental (LE) factors using artificial intelligence (AI) technologies. This represents a novel and potent approach to guide personalised interventions improving GBM patient care and QoL. In IPerGlio, clinical and immune parameters (phenotypical, molecular, functional, and imaging data sets) from 260 GBM patients from three centres will be integrated with LE data by Business Intelligence (BI). By applying AI generated models to these data, IPerGlio will deliver GBM prognostic markers driving decisions for combination treatment with immunotherapy in clinical trials. To improve the learning process, project-derived data will be cross-checked with public datasets (e.g., IVY GBM Atlas Project, GBM Bio Discovery Portal). The ethical challenges regarding data security and sharing posed by personalised medicine and AI approaches will be inclusively addressed by IPerGlio through active stakeholder and patient involvement. Thus, the IPerGlio project will strongly improve GBM clinical decision-making by identifying risk factors amenable to reinforce tertiary prevention and ensuring effective and responsible delivery of AI-guided personalised immunotherapy.
Network ERA PerMed
Call 5th Joint Transnational Call for Proposals (2022)

Project partner

Number Name Role Country
1 Oslo University Hospital Coordinator Norway
2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS Partner Italy
3 Instituto Superiore di Sanità Partner Italy
4 Luxembourg Institute of Health Partner Luxembourg
5 BioDonostia Health Research Institute Partner Spain
6 University Medical Center Goettingen Partner Germany